<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115838</url>
  </required_header>
  <id_info>
    <org_study_id>8591-043</org_study_id>
    <secondary_id>2021-003414-39</secondary_id>
    <secondary_id>MK-8591-043</secondary_id>
    <nct_id>NCT05115838</nct_id>
  </id_info>
  <brief_title>Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)</brief_title>
  <official_title>A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)&#xD;
      of an islatravir (ISL)-eluting implant. Participants will receive an implant placed in the&#xD;
      upper arm for approximately 52 weeks with 8 weeks of follow-up in the Base Study. A subset of&#xD;
      participants will also receive a second implant for an additional 12 weeks before 8 weeks of&#xD;
      follow-up in the Substudy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 13, 2021</start_date>
  <completion_date type="Anticipated">March 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 7, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with ≥1 adverse events (AEs)</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants withdrawing from study treatment due to adverse event (AE)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of islatravir (ISL) 12 weeks after placement of an ISL-eluting implant (ISL C12weeks)</measure>
    <time_frame>Week 12</time_frame>
    <description>Plasma ISL C12weeks will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of islatravir (ISL) 52 weeks after placement of an ISL-eluting implant (ISL C52weeks)</measure>
    <time_frame>Week 52</time_frame>
    <description>Plasma ISL C52weeks will be determined.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Islatravir 47 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an ISL 47 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Islatravir 52 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an ISL 52 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Islatravir 57 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an ISL 57 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive a placebo implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Islatravir</intervention_name>
    <description>ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.</description>
    <arm_group_label>Islatravir 47 mg</arm_group_label>
    <arm_group_label>Islatravir 52 mg</arm_group_label>
    <arm_group_label>Islatravir 57 mg</arm_group_label>
    <other_name>MK-8591</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo implantable rod placed subdermally on the upper arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is in good health&#xD;
&#xD;
          -  Is confirmed human immunodeficiency virus (HIV)-uninfected&#xD;
&#xD;
          -  Is at low risk of HIV infection&#xD;
&#xD;
          -  For males, uses contraception in accordance with local regulations regarding&#xD;
             contraception use for those participating in clinical trials&#xD;
&#xD;
          -  For females, is not pregnant or breastfeeding and one of the following applies:&#xD;
&#xD;
          -  Is not a participant of childbearing potential (POCBP)&#xD;
&#xD;
          -  Is a POCBP and uses an acceptable contraception method or is abstinent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has an active diagnosis of hepatitis (B or C) due to any cause&#xD;
&#xD;
          -  Has a history of malignancy ≤5 years before signing informed consent&#xD;
&#xD;
          -  Has a history or current evidence of any condition that might confound study results&#xD;
             or interfere with study participation&#xD;
&#xD;
          -  Has a history of keloid in upper arm or presence of tattoo, scar, or other physical&#xD;
             finding that could interfere with implant placement (the contralateral arm may be used&#xD;
             if the findings are limited to 1 arm)&#xD;
&#xD;
          -  Is taking or is expected to take immunosuppressants during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Islatravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

